A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Follow this author to personalize your feed and get instant alerts. WHY FOLLOW? Custom Feed: See the stories that matter most to you. Smart Alerts: Get notified about major news as it happens. Update ...

Add Futurism (opens Google in a new window or tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News ...

A lone developer has released an open-source, AI-generated alternative to Adobe's entire Creative Cloud suite, reigniting the hot debate over Adobe's subscription pricing and the disruptive power of ...

Adobe announced Thursday that it’s adding to its vast collection of artificial intelligence tools, this time with a focus on audio. The new Firefly AI tools use AI to generate speech, music and sound ...

Blocklists were already losing ground before AI entered the picture. Phishing domains have been getting shorter-lived for years, campaigns have been burning infrastructure faster, and the gap between ...

Google Forms is one of the easiest ways to collect data from customers and users, but it goes so far beyond that. Did you know Payable’s Google Forms extension adds secure payment options to your ...

Adobe has introduced Custom Models in public beta for Firefly, giving you a way to generate images in your own visual style instead of relying on generic AI outputs. By uploading your own images, you ...

Adobe is releasing a new capability in Firefly today called custom models. With it, creators, brands, and users in general can now train the model to follow their own illustration and photographic ...

Generate:Biomedicines has earmarked $300 million of its IPO funds to complete a pair of phase 3 asthma trials for its anti-TSLP antibody GB-0895. (Fabrice Cabaud/Stock/Getty Images Plus) ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...